Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ASBRON vs AEROLATE JR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Asbron is a combination product containing theophylline and guaifenesin. Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, resulting in bronchodilation and anti-inflammatory effects. Guaifenesin is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
Relief of symptoms of acute bronchial asthma and reversible bronchospasm associated with chronic bronchitis and emphysema,Symptomatic relief of productive cough associated with respiratory conditions
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
1-2 tablets (130-260 mg theophylline equivalent) orally every 6-8 hours; maximum 6 tablets/day.
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
4-6 hours in adults; prolonged to 8-12 hours in hepatic impairment or elderly patients
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Theophylline is primarily metabolized by cytochrome P450 enzymes, mainly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Guaifenesin is metabolized via oxidation and glucuronidation.
Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Primarily renal (70-80% as unchanged drug), biliary/fecal (~15-20% as metabolites and unchanged drug)
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
50-60% bound to albumin and alpha-1-acid glycoprotein
Approximately 70% bound to plasma proteins, primarily albumin.
0.3-0.5 L/kg; indicates distribution primarily into extracellular fluid
Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Oral: 40-60%; rectal: 50-70%; inhalation: 10-30%
Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
GFR 30-59 m L/min: reduce dose by 25-50%; GFR <30 m L/min: reduce dose by 50% and monitor serum theophylline levels.
No adjustment required as drug is primarily hepatically metabolized.
Child-Pugh Class A: reduce dose by 50%; Child-Pugh Class B or C: reduce dose by 75% and monitor serum theophylline levels.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Weight-based: 10-16 mg/kg/day theophylline equivalent divided every 6-8 hours; maximum 400 mg/day. Adjust based on serum levels.
Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
Elderly patients: initial dose of 130 mg orally every 8 hours; titrate gradually; monitor serum theophylline levels due to reduced clearance.
No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.
Theophylline has a narrow therapeutic index; serious adverse effects including seizures and arrhythmias can occur at levels close to therapeutic range. Do not exceed recommended doses. Use caution in patients with cardiac or hepatic impairment.
None.
Theophylline toxicity is dose-related; monitor serum levels. Caution in patients with peptic ulcer, hyperthyroidism, seizure disorders, or cardiovascular disease. Drug interactions with quinolones, macrolides, and cimetidine can increase theophylline levels.
Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Hypersensitivity to theophylline or guaifenesin, active peptic ulcer disease, seizure disorders (unless controlled), and severe cardiac arrhythmias.
Hypersensitivity to theophylline or any component of the formulation.
Avoid high-fat meals with extended-release formulations as they may alter absorption. Limit caffeine-containing foods/beverages (coffee, tea, chocolate) due to additive CNS stimulation. No significant food interactions with guaifenesin.
High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.
Asbron contains theophylline and guaifenesin. Theophylline: In first trimester, limited data suggest no major teratogenic risk (FDA category C). In second and third trimesters, no known teratogenicity but may cause fetal tachycardia, jitteriness, or transient neonatal effects (e.g., irritability, vomiting) due to transplacental passage. Guaifenesin: Limited human data; animal studies not indicative of teratogenicity. Overall, Asbron is considered relatively low risk, but non-pharmacologic measures preferred in first trimester.
FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Theophylline is excreted into breast milk with an average milk-to-plasma ratio of 0.67. Maximum milk concentration correlates with maternal serum levels. With typical maternal doses, infant serum levels may reach 2-4 mcg/m L, rarely causing irritability or poor feeding. Guaifenesin is likely minimally transferred. Asbron is considered compatible with breastfeeding; observe infant for signs of theophylline side effects (jitteriness, insomnia).
Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
Theophylline clearance increases by 20-30% in pregnancy due to increased hepatic metabolism and volume of distribution, particularly in second and third trimesters. Starting doses should be based on non-pregnant recommendations, but maintenance doses may need to be increased by up to 30% to achieve therapeutic levels. Monitor serum levels every 1-2 weeks and adjust dose to maintain trough 5-10 mcg/m L (lower end to minimize fetal exposure). Postpartum, clearance decreases rapidly; reduce dose and monitor levels closely to avoid toxicity.
Pregnancy may reduce plasma concentrations due to increased clearance; consider dose adjustment based on clinical response. Monitor for hypokalemia.
Asbron is a combination product containing theophylline and guaifenesin. Theophylline has a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L) due to variable metabolism. Guaifenesin is an expectorant but evidence for efficacy is limited. Avoid in patients with active peptic ulcer disease or seizure disorders. Cimetidine, fluoroquinolones, and macrolides increase theophylline levels; smoking and rifampin decrease levels.
AEROLATE JR (theophylline) is a bronchodilator used for asthma and COPD. Due to narrow therapeutic index, monitor serum levels (target 5-15 mcg/m L). Caffeine and smoking affect metabolism; smoking cessation may require dose reduction. Avoid in seizure disorders or peptic ulcer.
Take Asbron exactly as prescribed; do not crush or chew extended-release tablets.,Avoid excessive caffeine intake (coffee, tea, cola) as it may increase side effects.,Report symptoms of theophylline toxicity: nausea, vomiting, insomnia, tremors, fast heartbeat.,Do not stop abruptly; dosage tapering may be needed.,Stay hydrated to help guaifenesin work effectively.,Avoid alcohol as it may increase side effects like dizziness.
Take exactly as prescribed; do not change dose without consulting doctor.,Avoid excessive caffeine (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, seizures.,Do not smoke or abruptly stop smoking; notify doctor if smoking habits change.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ASBRON vs AEROLATE JR, answered by our medical review team.
ASBRON is a Bronchodilator that works by Asbron is a combination product containing theophylline and guaifenesin. Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, resulting in bronchodilation and anti-inflammatory effects. Guaifenesin is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity.. AEROLATE JR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ASBRON and AEROLATE JR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ASBRON is: 1-2 tablets (130-260 mg theophylline equivalent) orally every 6-8 hours; maximum 6 tablets/day.. The standard adult dose of AEROLATE JR is: 1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ASBRON and AEROLATE JR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ASBRON is classified as Category C. Asbron contains theophylline and guaifenesin. Theophylline: In first trimester, limited data suggest no major teratogenic risk (FDA category C). In second and third trimesters, no . AEROLATE JR is classified as Category C. FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used nea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.